Amphastar Pharmaceuticals (AMPH) vs Structure Therapeutics (GPCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Amphastar Pharmaceuticals (AMPH) has outperformed Structure Therapeutics (GPCR) over the past year, gaining 8.6% versus a loss of 53.0%. Amphastar Pharmaceuticals is the larger company by market cap ($1.20 billion vs $1.15 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMPH | GPCR |
|---|---|---|
| Share price | $28.25 | $16.13 |
| Market cap | $1.20B | $1.15B |
| 1-day change | +0.50% | -5.78% |
| YTD return | +5.49% | -76.81% |
| 1-year return | +8.61% | -53.00% |
| 5-year return | +41.89% | — |
| P/E ratio (TTM) | 12.96 | — |
| Forward P/E | 8.43 | — |
| EPS (TTM) | $2.18 | $-3.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $719.89M | — |
| Revenue growth (YoY) | -1.65% | — |
| Net income (latest FY) | $98.09M | $-141.20M |
| Gross margin | 49.46% | — |
| Operating margin | 19.50% | — |
| Net margin | 13.63% | — |
| 52-week high | $31.00 | $94.90 |
| 52-week low | $16.65 | $16.06 |
| Distance from 52-week high | -8.87% | -83.00% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -13.27% | +550.09% |
| Average volume | 475.35K | 1.18M |
| Shares outstanding | 42.65M | 71.59M |
| Employees | 1,976 | 281 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMPH has outperformed GPCR by 61.6 percentage points over the past year.
About Amphastar Pharmaceuticals
AMPH stock →Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
AMPH vs GPCR FAQ
Which is bigger, Amphastar Pharmaceuticals or Structure Therapeutics?
Amphastar Pharmaceuticals (AMPH) is larger, with a market capitalization of $1.20B compared with $1.15B for Structure Therapeutics (GPCR).
Which stock has performed better over the past year, AMPH or GPCR?
AMPH returned +8.61% over the past 12 months, compared with -53.00% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are Amphastar Pharmaceuticals and Structure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.